SOUTH SAN FRANCISCO, Calif. , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm , PhD, will present at the upcoming 43 rd Annual J.P. Morgan Healthcare Conference taking place on January 13 th - 16 th at
The KREX ™ offering provides additional high plex proteomic solutions for biopharma and translational research end markets SOUTH SAN FRANCISCO, Calif. November 21, 2024 -- Standard BioTools Inc. (Nasdaq: LAB) ("Standard BioTools" or the "Company") today announced the addition of KREX™ precision
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024 . Kim, a co-founder and most recently Chief Operating
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12 th , 2024 President and CEO,
SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024 . Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing
SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024 , after the close of the market. The Company’s management will host a conference call and
Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurology SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that the SomaScan ® 11K Platform now includes protein
Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with clinical measures of liver disease SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm , PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September
SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August: Canaccord Genuity 44 th Annual Growth Conference on August 13 th , 2024
